2018
Polycystic ovarian syndrome
Pal L, Pathy S. Polycystic ovarian syndrome. 2018, 117-129. DOI: 10.1002/9781119072980.ch12.ChaptersPolycystic ovarian syndromeOvulatory dysfunctionOvarian syndromeRisk of complicationsOverall health riskNeonatal complicationsGestational diabetesAndrogen excessCesarean sectionFetal macrosomiaOperative deliveryPolycystic ovariesClinical manifestationsTreatment modalitiesMetabolic disordersDiagnostic criteriaBody hairLaboratory evaluationWomenComplicationsDysfunctionIndividual womenUnique risksSyndromeRisk
2017
Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature.
Gressel G, Buza N, Pal L. Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature. European Journal Of Gynaecological Oncology 2017, 38: 214-220. PMID: 29953783.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansHyperandrogenismHysterectomyMiddle AgedNeoadjuvant TherapyNeoplasm GradingOvarian NeoplasmsOvariectomyPostmenopauseRetrospective StudiesSalpingectomySertoli-Leydig Cell TumorConceptsSertoli-Leydig cell tumorOvarian Sertoli-Leydig cell tumorPresent patient populationDisease-free survivalSingle institution experienceTertiary care institutionTime of diagnosisOnset of menopauseRisk of recurrenceSeries of casesAdjuvant chemotherapyMedian followPostmenopausal bleedingPostmenopausal patientsMedian ageMedian intervalClinical presentationDefinitive managementPathological findingsRetrospective reviewInstitution experiencePatient populationTreatment modalitiesCell tumorsTumor grade